Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

COX-2 expression not an adequate independent prognostic factor: Research

Cyclooxygenase-2 represents a key modulatory molecule in inflammation and carcinogenesis. COX-2 is known to have multiple tumorigenic effects. Increased expression of COX-2 has been observed in a variety of tumors including pancreatic cancer.

22 Apr 2010

Research findings may help personalize use of statins, scientists say

Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered why statins -- popular drugs that lower cholesterol and appear to protect against colorectal cancer development -- work for some people, but not for all.

22 Apr 2010

NO-naproxen blocks molecular changes leading to colorectal cancer development

Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.

22 Apr 2010

Study: Scientists advance toward development of urine test for detecting colon cancer

Scientists are reporting an advance toward development of a urine test for detecting colon cancer, the third most common cancer in the United States. Such a test could eventually compliment or even reduce the need for colonoscopy, the mainstay screening test used today. The study, which analyzes chemical differences in the urine of humans with and without colon cancer, is in ACS' Journal of Proteome Research, a monthly publication.

22 Apr 2010

Abbott's first-quarter worldwide pharmaceutical sales increases by 12.9%

Abbott today announced financial results for the first quarter ended March 31, 2010.

21 Apr 2010

Study helps understand molecular mechanism underlying taurine's protection against hepatic fibrosis

Hepatic fibrosis (HF) occurs in most types of chronic liver diseases and approximately 25%-40% of HF cases may ultimately progress to hepatic cirrhosis. Hepatic stellate cells (HSCs) contribute significantly to the occurrence of HF and the activation of HSC is the key issue in the pathogenesis of HF. Taurine is a kind of important anti-injury substance in the body.

21 Apr 2010

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Alchemia's subsidiary Alchemia Oncology today presented two posters at the American Association of Cancer Research (AACR) 101st Annual Meeting in Washington, DC. The data demonstrates the ability of the Company's HyACT tumour targeting technology to dramatically enhance the killing of cancer stem cells. These cells are highly resistant to treatment with chemotherapeutic drugs and are believed to be responsible for treatment failure and disease recurrence.

21 Apr 2010

Immunomedics reports study results of antibody-SN-38 conjugates for targeted cancer chemotherapy

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, reported today at the 101st Annual Meeting of the American Association for Cancer Research (AACR) results from two studies aimed at improving the design of antibody-SN-38 conjugates for targeted cancer chemotherapy.

21 Apr 2010

Preclinical data in neuroblastoma for perifosine to be presented at AACR 2010 Meeting

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that preclinical data in neuroblastoma for perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, will be presented at the 101st Annual Meeting of the American Association for Cancer Research, currently being held at the Walter E. Washington Convention Center in Washington, DC.

21 Apr 2010

Researchers demonstrate role of HSP-90 in portal hypertension

Neural vasoregulation represents a rapid and potent mode of altering vascular tone but has not been investigated thoroughly during portal hypertension. Heat shock protein-90 is well-known to act as a molecular chaperone optimizing endothelial and neural NO-synthase enzyme activity and thus, NO production.

21 Apr 2010

Gene test predicts statins' effectiveness in reducing risk of colorectal cancer

A genetic test can help determine in which patients cholesterol-lowering statin drugs might have the most benefit in also reducing the risk of colorectal cancer, a new study from researchers at the University of Michigan Comprehensive Cancer Center finds.

21 Apr 2010

miRNAs may generate new insights on cancer and possible future treatments

Scientists are methodically unlocking the biological processes that lead to cancer, and recent discoveries with microRNAs (miRNAs) are revolutionizing their understanding and leading to clinical trials of potentially effective treatments.

21 Apr 2010

Diagnosis of gastric adenomyoma remains a challenging issue

Gastric adenomyoma (AM) is a rare, benign tumor, characteristically composed of glands and cysts, lined by columnar, flattened epithelia and a prominent smooth muscle stroma. Patients with gastric AM may be asymptomatic, or present as nonspecific gastrointestinal symptoms.

21 Apr 2010

Poster on dual Erk/PI3K inhibitors presented at AACR 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today presented a poster on dual Erk/PI3K inhibitors and made an oral presentation on its selective Erk inhibitors, at the American Association for Cancer Research Annual Meeting in Washington, D.C.

21 Apr 2010

New research indicates patients may develop anemia after gastric bypass surgery

Morbid obesity is one of the most common causes of morbidity and mortality in Western countries. Roux-en-Y gastric bypass (RYGB) has become a common procedure for achieving short- and long-term weight loss. It has gained great popularity among surgeons and patients in recent years. Long

21 Apr 2010

Celsion's ThermoDox Phase I trial data presented at 9th IHPBA World Congress

Celsion Corporation today announced that Dr. Thanjavur S. Ravikumar, from the Geisinger Health System and a principal investigator of the Phase I ThermoDox® dose escalation trial, gave an oral presentation at the Liver Tumors Panel session of the 9th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA) in Buenos Aires, Argentina.

21 Apr 2010

Aeterna Zentaris raises $13.7M through registered direct offering

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has completed its previously announced registered direct offering of US$15 million of units comprised of common shares and common share purchase warrants to certain institutional investors.

20 Apr 2010

Temporary occlusion of portal vein may help avoid I/R-related complications in liver surgery

Liver surgery has become a safe procedure in the past years and is mainly done because of malignant tumors. A common strategy to reduce blood loss during surgery is to temporarily shut down the blood supply to the liver [pringle maneuver], which, however may be associated with severe hepatocellular injury and consequent enhanced morbidity.

20 Apr 2010

National health care reform package promises to reduce number of uninsured Americans

The national health care reform package signed by President Obama recently promises to significantly reduce the number of uninsured Americans. According to the Congressional Budget Office, 31 million Americans who are currently uninsured will gain health care coverage under the federal legislation.

20 Apr 2010

MicroStockProfit.com releases investment report on AEterna Zentaris

MicroStockProfit.com announces an investment report featuring AEterna Zentaris Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

20 Apr 2010